Published on
March 30, 2025
- 15:30 GMT
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), …
Distribution channels:
Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry
...
